Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-D-g1ucose modified SPIOs

Eur J Radiol. 2012 Jan;81(1):95-9. doi: 10.1016/j.ejrad.2011.03.013. Epub 2011 Mar 26.

Abstract

Glucose transporter (Glut), a cellular transmembrane receptor, plays a key role in cell glucose metabolism and is linked to a poor prognosis in various human cancers. In this study, we prepared γ-Fe(2)O(3) NPs coated with DMSA, in which modified with 2-DG, then γ-Fe(2)O(3)@DMSA-DG NPs was constructed. The specific interactions between Glut1-overexpressing tumor cells (MDA-MB-231) and γ-Fe(2)O(3)@DMSA-DG NPs were observed using Prussian blue staining and transmission electron microscope (TEM), and found that γ-Fe(2)O(3)@DMSA-DG NPs were absorbed targetedly by the cells. Furthermore, the capacity of transporting SPIOs into tumor cells using these γ-Fe(2)O(3)@DMSA-DG NPs was evaluated with a 1.5 T clinical magnetic resonance imaging (MRI) scanner. It was found that the acquired MRI T2 signal intensity of MDA-MB-231 cells that were treated with the γ-Fe(2)O(3)@DMSA-DG NPs decreased significantly, and it was inhibited by competition with antibody of Glut1. Our results suggest that γ-Fe(2)O(3)@DMSA-DG NPs are a useful targeting to Glut1-overexpressing tumor cells in vitro and that γ-Fe(2)O(3)@DMSA-DG NPs may serve as a MRI-targeted tumor agent for better tumor imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology*
  • Cell Line, Tumor
  • Contrast Media / pharmacokinetics
  • Deoxyglucose / pharmacokinetics*
  • Dextrans / pharmacokinetics*
  • Glucose Transporter Type 1 / metabolism*
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Magnetite Nanoparticles*
  • Up-Regulation

Substances

  • Contrast Media
  • Dextrans
  • Glucose Transporter Type 1
  • Magnetite Nanoparticles
  • SLC2A1 protein, human
  • ferumoxtran-10
  • Deoxyglucose